Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 41 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cerebral Thromboembolism Clear all
Completed Phase 3 Interventional Results available

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

NCT02111564
View directory record Official record
Conditions
Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases
Interventions
Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
135
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 1, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

NCT01674647
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 1, 2026, 9:30 PM EDT
Withdrawn Phase 4 Interventional

Timing of VTE Prophylaxis in TBI

NCT03081169
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), VTE (Venous Thromboembolism)
Interventions
Enoxaparin Sodium 150 MG/ML Prefilled Syringe, Heparin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 1, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

NCT02585713
View directory record Official record
Conditions
Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis, Malignant Neoplasm, Mesenteric Thrombosis, Metastatic Malignant Neoplasm, Portal Vein Thrombosis, Pulmonary Embolism, Renal Vein Thrombosis, Splenic Thrombosis, Venous Thromboembolism
Interventions
Apixaban, Dalteparin, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
18
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 1, 2026, 9:30 PM EDT
Active, not recruiting No phase listed Observational

Florida Cerebrovascular Disease Biorepository and Genomics Center

NCT05491980
View directory record Official record
Conditions
Cerebrovascular Disease, Ischemic Stroke, Transient Ischemic Attack, Intracerebral Hemorrhage, Aneurysmal Subarachnoid Hemorrhage, Vascular Dementia, Anoxic Brain Injury, Unruptured Intracranial Aneurysm, Carotid Artery Stenosis Symptomatic, Asymptomatic Carotid Artery Stenosis, Non-Aneurysmal Perimesencephalic Subarachnoid Haemorrhage, Cerebral Venous Thrombosis, Moyamoya Disease, Fibromuscular Dysplasia, Subarachnoid Hemorrhage, Leukoaraiosis, Arteriovenous Fistula, Reversible Cerebral Vasoconstriction Syndrome, CADASIL
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 1, 2026, 9:30 PM EDT
Active, not recruiting No phase listed Observational

Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events

NCT06855394
View directory record Official record
Conditions
Atherosclerotic Vascular Disease, Coronary Arterial Disease (CAD), Atherosclerosis of Coronary Artery, Atherosclerosis of Arteries of the Extremities, Unspecified, Heart Diseases, Stroke, Venous Thromboembolic Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 1, 2026, 9:30 PM EDT
Completed No phase listed Observational

Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas

NCT00253669
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Thromboembolism
Interventions
laboratory biomarker analysis, physiologic testing, management of therapy complications
Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 1, 2026, 9:30 PM EDT
Terminated Phase 3 Interventional

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

NCT00580216
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
162
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 1, 2026, 9:30 PM EDT
Not listed No phase listed Observational

Biomarkers of Acute Stroke in Clinic

NCT03897478
View directory record Official record
Conditions
Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Interventions
ISCDX blood test
Diagnostic Test
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 1, 2026, 9:30 PM EDT
Terminated Phase 3 Interventional

Right to Left Cardiac Shunt Detection

NCT01773252
View directory record Official record
Conditions
Right to Left Shunt, Patent Foramen Ovale, Atrial Septal Defect
Interventions
Flow Detection System
Device
Lead sponsor
Cardiox Corporation
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 1, 2026, 9:30 PM EDT
Active, not recruiting No phase listed Observational

REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

NCT05611918
View directory record Official record
Conditions
Intra Cerebral Hemorrhage, ICH - Intracerebral Hemorrhage, ICH, Hemorrhage, Stroke, Clot (Blood); Brain, Clot Blood, Cognitive Decline, Cognitive Impairment, Survivorship, Memory Impairment, Motor Activity
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 1, 2026, 9:30 PM EDT
Completed No phase listed Observational

Safety and Feasibility of the Infinity Catheter for Radial Access

NCT04553549
View directory record Official record
Conditions
Brain Tumor, Stroke, Acute, Brain Aneurysm, Intracranial Arteriovenous Malformations, Carotid Stenosis, Cavernous Sinus Thrombosis
Interventions
Transradial approach
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 1, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional Results available

Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma

NCT00790452
View directory record Official record
Conditions
Glioblastoma
Interventions
Aspirin, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 1, 2026, 9:30 PM EDT
Terminated Phase 3 Interventional Results available

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

NCT02313909
View directory record Official record
Conditions
Stroke
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
7,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
38
States / cities
Tucson, Arizona • Long Beach, California • Stanford, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 1, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease

NCT00071032
View directory record Official record
Conditions
Anemia, Hematologic Diseases, Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Thromboembolism, Pneumonia, Cerebrovascular Accident
Interventions
Liberal (10 g/dL) Transfusion Strategy, Restrictive (Symptomatic) Transfusion Strategy
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
50 Years and older
Enrollment
2,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 1, 2026, 9:30 PM EDT
Completed No phase listed Observational

COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications

NCT04535128
View directory record Official record
Conditions
Covid19, Thrombosis Embolism, DVT, Pulmonary Embolism, Myocardial Infarction, Stroke
Interventions
No intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
11,000 participants
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 1, 2026, 9:30 PM EDT
Completed No phase listed Observational

Thrombosis Outcomes in Pediatric Venous Thromboembolism

NCT03068923
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 1, 2026, 9:30 PM EDT